Peritoneal Immunity Group
The focus of our research is the understanding of the mechanisms controlling inflammation-driven membrane damage in peritoneal dialysis patients.
Peritoneal Immunity Group
Renal replacement therapy is a chronic condition associated with significant morbidity and mortality and requires daily therapeutic intervention.
While there remains no cure for renal deterioration and the number of available kidney donors is limited, chronic dialysis remains an essential daily life-saving treatment modality.
Treatment with Peritoneal Dialysis (PD) offers significant treatment, lifestyle, and quality of life advantages over hospital haemodialysis.
In addition, it is a more cost-effective therapy. The “Achilles’ heel” of PD, however, remains the susceptibility to recurrent infection with detrimental effects on the process of dialysis through direct membrane damage, but also in more severe infection through significant morbidity and mortality.
- Rhodes, D. A. et al., 2015. Activation of human γδ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. Journal of Immunology 194 (5), pp.2390-2398. (10.4049/jimmunol.1401064)
- Stack, G. et al. 2015. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathogens 11 (2) e1004641. (10.1371/journal.ppat.1004641)
- Rosser, E. C. et al., 2014. Regulatory B cells are induced by gut microbiota- driven interleukin-1β and interleukin-6 production. Nature Medicine 20 , pp.1334-1339. (10.1038/nm.3680)
- Davey, M. S. et al., 2014. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. Journal of Immunology 193 (7), pp.3704-3716. (10.4049/jimmunol.1401018)
- Pitzalis, C. et al., 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Reviews Immunology 14 (7), pp.447-462. (10.1038/nri3700)
PERIT-PD: Patient immune responses to infection in Peritoneal Dialysis
Peritonitis remains the main reason for treatment failure in peritoneal dialysis (PD) patients. Despite this the peritoneal immune response to specific pathogens remains poorly defined.
This project intends to collect a large number of defined samples from patients to characterise the immune response and use this to develop potential methods for better diagnosis, treatment and monitoring of infection in these patients.
EuTRiPD: European Training & Research in Peritoneal Dialysis
Long term clinical studies in peritoneal dialysis
Our long term strategy being a better understanding of the natural history of the structural and functional alterations that occur in the peritoneum of peritoneal dialysis patients limiting time on therapy.
The Biopsy Registry
An international observational study, with collections in the UK, France, Spain and Japan providing samples of dialysed peritoneum for analysis.
The Global Fluid Study
Reader, Division of Infection and Immunity. Engagement Lead, Systems Immunity Research Institute.
- +44 (0)29 2068 7011